Research programme: kinase inhibitors - Carna Biosciences/Sumitomo Dainippon Pharma

Drug Profile

Research programme: kinase inhibitors - Carna Biosciences/Sumitomo Dainippon Pharma

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Carna Biosciences; Sumitomo Dainippon Pharma
  • Class Antipsychotics; Neuroprotectants; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurological disorders; Psychiatric disorders

Most Recent Events

  • 27 Mar 2018 Carna Biosciences and Sumitomo Dainippon Pharma agree to co-develop kinase inhibitors for psychiatric and neurological disorders
  • 27 Mar 2018 Early research in Neurological disorders in Japan
  • 27 Mar 2018 Early research in Psychiatric disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top